{"id":"https://openalex.org/W1994037441","doi":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","title":"The CCK\u2010B Antagonist CI\u2010988 Increases Dopamine Levels in Microdialysate from the Rat Nucleus Accumbens via a Tetrodotoxin\u2010 and Calcium\u2010Independent Mechanism","display_name":"The CCK\u2010B Antagonist CI\u2010988 Increases Dopamine Levels in Microdialysate from the Rat Nucleus Accumbens via a Tetrodotoxin\u2010 and Calcium\u2010Independent Mechanism","publication_year":1995,"publication_date":"1995-07-01","ids":{"openalex":"https://openalex.org/W1994037441","doi":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","mag":"1994037441","pmid":"https://pubmed.ncbi.nlm.nih.gov/7790862"},"language":"en","primary_location":{"id":"doi:10.1046/j.1471-4159.1995.65010208.x","doi":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","is_oa":false,"landing_page_url":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","pdf_url":null,"source":{"id":"https://openalex.org/S135837084","display_name":"Journal of Neurochemistry","issn_l":"0022-3042","issn":["0022-3042","1471-4159"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neurochemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110128470","display_name":"Rebecca L. Corwin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210158500","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210158500"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca L. Corwin","raw_affiliation_strings":["Section on Behavioral Neuropharmacology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1380, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Behavioral Neuropharmacology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1380, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210158500"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043199174","display_name":"Andreas J\u00f6rn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210158500","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210158500"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreas J\u00f6rn","raw_affiliation_strings":["Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","National Institutes of Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210158500"]},{"raw_affiliation_string":"National Institutes of Health","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075930172","display_name":"Melva Hardy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210158500","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210158500"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melva Hardy","raw_affiliation_strings":["Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","National Institutes of Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210158500"]},{"raw_affiliation_string":"National Institutes of Health","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063501456","display_name":"Jacqueline N. Crawley","orcid":"https://orcid.org/0000-0002-1224-995X","observed_orcids":["https://orcid.org/0000-0002-1224-995X"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210158500","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210158500"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jacqueline N. Crawley","raw_affiliation_strings":["Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","National Institutes of Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, U.S.A","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210158500"]},{"raw_affiliation_string":"National Institutes of Health","institution_ids":["https://openalex.org/I1299303238"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5063501456"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210158500"],"apc_list":{"value":5330,"currency":"USD","value_usd":5330},"apc_paid":null,"fwci":0.4,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.50943804,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"65","issue":"1","first_page":"208","last_page":"217"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.7451000213623047,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.7451000213623047,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.17419999837875366,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.07039999961853027,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ci-988","display_name":"CI-988","score":0.984000027179718},{"id":"https://openalex.org/keywords/dopamine-overflow","display_name":"dopamine overflow","score":0.8550000190734863},{"id":"https://openalex.org/keywords/nucleus-accumbens","display_name":"nucleus accumbens","score":0.9959999918937683},{"id":"https://openalex.org/keywords/caudate-nucleus","display_name":"caudate nucleus","score":0.8920000195503235},{"id":"https://openalex.org/keywords/cck-a-receptor","display_name":"CCK-A receptor","score":0.8500000238418579},{"id":"https://openalex.org/keywords/tetrodotoxin-insensitivity","display_name":"tetrodotoxin insensitivity","score":0.8619999885559082}],"concepts":[{"id":"https://openalex.org/C2776552330","wikidata":"https://www.wikidata.org/wiki/Q1476178","display_name":"Nucleus accumbens","level":3,"score":0.9323087930679321},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.6937868595123291},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6891497373580933},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6297719478607178},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.5348367094993591},{"id":"https://openalex.org/C2776741303","wikidata":"https://www.wikidata.org/wiki/Q379842","display_name":"Tetrodotoxin","level":2,"score":0.5227630138397217},{"id":"https://openalex.org/C107539642","wikidata":"https://www.wikidata.org/wiki/Q5104299","display_name":"Cholecystokinin B receptor","level":4,"score":0.4947630763053894},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.435243159532547},{"id":"https://openalex.org/C50156730","wikidata":"https://www.wikidata.org/wiki/Q3856966","display_name":"Microdialysis","level":3,"score":0.4115796685218811},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.398580402135849},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36101800203323364},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.34563201665878296},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.23032328486442566},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.16232633590698242},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12325561046600342},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.036638230085372925},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002118","descriptor_name":"Calcium","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002766","descriptor_name":"Cholecystokinin","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008536","descriptor_name":"Meglumine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D008536","descriptor_name":"Meglumine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009714","descriptor_name":"Nucleus Accumbens","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D013779","descriptor_name":"Tetrodotoxin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017551","descriptor_name":"Microdialysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1046/j.1471-4159.1995.65010208.x","doi":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","is_oa":false,"landing_page_url":"https://doi.org/10.1046/j.1471-4159.1995.65010208.x","pdf_url":null,"source":{"id":"https://openalex.org/S135837084","display_name":"Journal of Neurochemistry","issn_l":"0022-3042","issn":["0022-3042","1471-4159"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neurochemistry","raw_type":"journal-article"},{"id":"pmid:7790862","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7790862","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of neurochemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2081936754","https://openalex.org/W2006209193","https://openalex.org/W2031367403","https://openalex.org/W2083186924","https://openalex.org/W1982019262","https://openalex.org/W2057262167","https://openalex.org/W2069854977","https://openalex.org/W2046604017","https://openalex.org/W2296689965","https://openalex.org/W2079791307"],"abstract_inverted_index":{"CI-988,":[0,71],"a":[1,9],"water-soluble,":[2],"selective":[3,123],"cholecystokinin-B":[4],"antagonist,":[5],"was":[6,100],"perfused":[7],"through":[8],"microdialysis":[10],"probe":[11],"into":[12],"the":[13,47,61,66,78,82,92,97],"anterior":[14],"nucleus":[15,18,22,79],"accumbens,":[16,19],"posterior":[17],"or":[20],"caudate":[21],"of":[23,28,57,70,84,94],"anesthetized":[24],"rats.":[25],"High":[26],"concentrations":[27],"CI-988":[29,48,58,85,112],"produced":[30],"three-":[31],"to":[32,52,86,103,118],"fivefold":[33],"increases":[34,113],"in":[35,77,91,96],"dopamine":[36,75,88,114],"overflow,":[37],"at":[38],"all":[39],"three":[40],"sites,":[41],"that":[42],"were":[43],"temporally":[44],"correlated":[45],"with":[46],"perfusion":[49],"and":[50,65,99,129],"returned":[51],"baseline":[53],"levels":[54],"upon":[55],"cessation":[56],"perfusion.":[59],"However,":[60],"cholecystokinin-A":[62],"antagonist":[63],"CAM-1481,":[64],"relatively":[67],"inactive":[68],"enantiomer":[69],"CAM-1241,":[72],"also":[73],"increased":[74],"overflow":[76,89,115],"accumbens.":[80],"Furthermore,":[81],"ability":[83],"increase":[87],"persisted":[90],"absence":[93],"calcium":[95],"perfusate":[98],"not":[101,117,122],"sensitive":[102],"tetrodotoxin":[104],"treatment.":[105],"The":[106],"mechanism":[107],"by":[108],"which":[109],"locally":[110],"administered":[111],"appears":[116],"be":[119,131],"anatomically":[120],"specific,":[121],"for":[124],"one":[125],"cholecystokinin":[126],"receptor":[127],"subtype,":[128],"may":[130],"nonvesicular.":[132]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}